Analyst consensus rating
Silence Therapeutics Analyst Rating: none
SLN is rated none by 6 analysts with a $33.00 target. As of 2026-08-30.
Direct answer
Silence Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.00.
Forecast evidence checked August 30, 2026.
Get free Silence Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.42
- Average price target
- $33.00
- High price target
- $75.00
- Low price target
- $10.00
- Low target gap
- -25.5%
- Target upside
- +145.9%
- High target gap
- +458.9%
- Target range width
- 484.4%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Silence Therapeutics?
Silence Therapeutics has a verified none consensus. The same dataset has an average price target of $33.00.
How far are Silence Therapeutics's low and high targets from the recorded price?
The low target implies -25.5%, while the high target implies +458.9%.
How many analysts are included in Silence Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Silence Therapeutics's target upside or downside calculated?
The average target of $33.00 is divided by the recorded price of $13.42, then one is subtracted to produce +145.9%. This does not guarantee a future return.
When was Silence Therapeutics's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.